October 3rd 2024
Acalabrutinib, a BTK inhibitor, has shown promising results in treating mantle cell lymphoma, with the FDA granting it priority review.
September 20th 2024
September 19th 2024
September 18th 2024
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Higher Response Elicited With Initial Higher-Dose Duvelisib in Patients With R/R PTCL
December 9th 2019The administration of a higher initial dose of duvelisib at 75 mg BID led to a higher overall response rate of 62% compared with 40% in patients with relapsed/refractory peripheral T-cell lymphoma who received 25 mg BID, according to data from the dose-optimization phase of the PRIMO trial presented at the 2019 American Society of Hematology Annual Meeting.<br />
Read More
Zanubrutinib Highly Effective in CLL/SLL, Despite Presence of High-Risk Cytogenetics
December 9th 2019In the SEQUOIA trial, zanubrutinib, a Bruton’s tyrosine kinase inhibitor, showed continued high overall response rates for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma, regardless of deletion 17p status, according to findings presented at the American Socitey of Hematology Annual Meeting and Exposition.
Read More
In the final analysis of the GADOLIN study in patients with rituximab-refractory indolent non-Hodgkin lymphoma, the combination of obinutuzumab plus bendamustine reduced the risk of progression or death by 43% compared with bendamustine alone. In patients with follicular lymphoma, the reduction was 49%.
Read More
LOXO-305 Shows High Efficacy in Patient With Heavily Pretreated B-cell Malignancies
December 9th 2019Treatment with LOXO-305 prompted responses from more than half of patients with heavily pretreated B-cell malignancies, including patients with resistance or intolerance to other BTK inhibitors or BCL2 inhibitors, according to findings from the phase I/II BRUIN trial presented at the 2019 American Society of Hematology Annual Meeting and Exposition.
Read More
Lenalidomide/Obinutuzumab Elicits 100% ORR in Rituximab-Refractory Indolent Non-Hodgkin Lymphoma
December 9th 2019A 100% overall response rate was achieved with the combination of lenalidomide and obinutuzumab in patients with relapsed indolent non-Hodgkin lymphoma that was refractory to rituximab, according to findings of a single-arm, phase I/II trial presented at the 2019 American Society of Hematology Annual Meeting and Exposition.<br />
Read More
Findings from a subgroup analysis of the phase III AUGMENT trial of patients aged 70 or older with indolent non-Hodgkin lymphoma showed a 34% reduction in the risk of disease progression or death compared with rituximab plus placebo, according data presented at the 2019 American Society of Hematology Annual Meeting and Exposition.<br />
Read More
Triplet Therapy Induced CR in R/R CLL
December 9th 2019In a phase I/II dose escalation study, there was a complete remission rate of 44% in patients with relapsed/refractory chronic lymphocytic leukemia receiving umbralisib, ublituximab, and venetoclax, according to findings presented at the 2019 ASH Annual Meeting.
Read More
Fixed-Duration Venetoclax Plus Obinutuzumab Improves PFS With High Undetectable MRD Rates in CLL
December 9th 2019Fixed-duration treatment with the combination of venetoclax plus obinutuzumab results in superior progression-free survival and high rates of undetectable minimal residual disease in patients with previously untreated chronic lymphocytic leukemia than chlorambucil plus obinutuzumab.
Read More
High Rates of CR Observed in Follicular Lymphoma With Triplet Regimen
December 8th 2019Patients with relapsed/refractory follicular lymphoma showed durable responses with the combination of polatuzumab-vedotin, obinutuzumab, and lenalidomide, according to results presented at the 2019 ASH Annual Meeting.
Read More
Obinutuzumab Plus Lenalidomide Shows Promise in High Tumor Burden Follicular Lymphoma
December 8th 2019Obinutuzumab combined with lenalidomide resulted in early and very high complete response rates in previously untreated patients with follicular lymphoma in a single-center phase II study. At a median follow-up of 25 months, the 2-year progression-free survival was 96%.
Read More
Triplet Therapy With Acalabrutinib Has Activity in Chronic Lymphocytic Leukemia
December 8th 2019An open-label, single-arm, phase II study in patients with chronic lymphocytic leukemia demonstrated the frontline AVO triplet, comprised of acalabrutinib, venetoclax, and obinutuzumab, achieved undetectable minimal residual disease in the bone marrow in 48% of patients after only 8 monthly cycles of therapy, according to lead author Benjamin L. Lampson, MD, PhD, who presented the findings at the 2019 ASH Annual Meeting.
Read More
Favorable PFS Continues to be Observed With Ibrutinib/Rituximab in CLL
December 8th 2019Updated follow-up analysis of the phase III E1912 study showed that ibrutinib/rituximab induced higher rates of progression-free survival (PFS) when compared against fludarabine, cyclophosphamide, and rituximab in patients ≤70 years with previously untreated chronic lymphocytic leukemia (CLL), according to Tait D. Shanafelt, MD, who presented the findings at the 2019 ASH Annual Meeting.
Read More
Undetectable MRD Is Reached in Patients With CLL Receiving First-Line Ibrutinib/Venetoclax
December 8th 2019Patients <70 years old with chronic lymphocytic leukemia treated in the minimal residual disease (MRD)–cohort of the phase II CAPTIVATE trial had undetectable MRD rates of 75% and 72% in the peripheral blood and bone marrow, respectively, with the frontline combination of ibrutinib and venetoclax, according to findings presented at the 2019 ASH Annual Meeting.
Read More
Three-Year Overall Survival Data Reported for Axi-Cel in B-Cell Lymphoma
December 8th 2019Patients with refractory large B-cell lymphoma who were treated with Axi-cel had a 3-year overall survival rate of 47%, according to an updated analysis of the phase II ZUMA-1 trial.
Read More
Durable Complete Remissions Achieved in NHL Following CAR T
December 8th 2019Complete remissions were achieved in greater than 20% of patients with highly refractory non-Hodgkin lymphomas who had been previously been treated with chimeric antigen receptor T-cell therapy with Mosunetuzumab, a novel bispecific antibody, according to study results presented at the 2019 American Society of Hematology Annual Meeting.
Read More
Patients With CLL Treated on the ELEVATE-TN Trial Experience Improved PFS With Acalabrutinib
December 8th 2019Patients with treatment-naïve chronic lymphocytic leukemia experienced a statistically significant improvement in progression-free survival with acalabrutinib as a single agent or in combination with obinutuzumab when compared with obinutuzumab plus chlorambucil, according to results from the phase III ELEVATE-TN trial presented at the 2019 ASH Annual Meeting.
Read More
Encouraging signs of dose-dependent efficacy, as well as a promising safety profile, were observed in patients with heavily pretreated relapsed/refractory multiple myeloma who were treated with CC-93269, a human IgG1-based T-cell engager that binds to BCMA and CD3 epsilon in a 2+1 format.
Read More
CAR T-Cell Therapy Targeting BCMA and CD38 Induces Positive Responses in Multiple Myeloma
December 8th 2019Patients with a difficult-to-treat form of multiple myeloma who were treated with a novel, bispecific anti-BCMA/anti-CD38 chimeric antigen receptor (CAR) T-cell therapy experienced promising responses and a manageable safety profile, according to results of a study that were presented at the 61st Annual American Society of Hematology Annual Meeting and Exposition.<br />
Read More
Preclinical Evidence Generates Buzz Around Novel Off-the-Shelf CAR NK Therapy
December 7th 2019A multi-antigen off-the-shelf chimeric antigen receptor natural killer cell therapy has been included in the ASH annual meeting spotlight due to exciting preclinical evidence. An investigational new drug application was approved in September 2019 for the therapy, labeled as FT596, developed by Fate Therapeutics, and human trials are scheduled to start in the first quater of 2020.
Read More
Contemporary Therapy for Advanced- Stage Hodgkin Lymphoma
December 6th 2019Hodgkin lymphoma represents approximately 10% of all cases of malignant lymphoma. This group of diseases most commonly affects adolescent and young adults, although approximately 20% to 25% of patients are aged ≥60 years at diagnosis.
Read More
Phase II Evaluates Vemurafenib/Obinutuzumab in Hairy Cell Leukemia
December 6th 2019Justin Taylor, MD, discusses the rationale for an ongoing phase II trial that is exploring the combination of vemurafenib, a BRAF inhibitor, plus the anti-CD20 monoclonal antibody obinutuzumab in previously untreated patients with classical hairy cell leukemia.
Watch
Onvansertib May Be a New Frontline Option for Patients With Venetoclax-Resistant AML
December 5th 2019Onvansertib inhibits tumor growth in patients with acute myeloid leukemia who are resistant to venetoclax, according to the in-vitro and in-vivo data from a phase II trial announced in a press release issued by Trovagene, Inc.
Read More
FDA Grants Breakthrough Designation to Abatacept for Prevention of Acute GVHD
December 4th 2019Abatacept has been granted a Breakthrough Therapy Designation by the FDA for the prevention of moderate to severe acute graft-versus-host disease in hematopoietic stem cell transplants from unrelated donors.
Read More
Phase II Devimstat Study Expanded to Increase Access for Patients With Burkitts Lymphoma/Leukemia
December 4th 2019A phase II study of experimental anti-mitochondrial drug devimstat in patients with relapsed/refractory Burkitt’s lymphoma/leukemia has been expanded to include patients at Massachusetts General Hospital in Boston, Massachusetts, according to a press release from Rafael Pharmaceuticals, Inc.
Read More
Brentuximab Vedotin Adds Benefit to A+AVD Therapy in cHL
December 3rd 2019Andrew M. Evens, DO, MSc, discusses the significance of the results from the phase III ECHELON-1 trial in which patients with stage III/IV classical Hodgkin lymphoma were treated with the combination of brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine.
Watch
A Look Back at FDA News from November 2019
December 2nd 2019In November 2019, the FDA approved a number of treatments, including acalabrutinib for the treatment of chronic lymphocytic leukemia and small lymphocytic leukemia, as well as zanubrutinib for the treatment of mantle cell lymphoma. A biosimilar for pegfilgrastim was also approved under indications.
Read More